Ertapenem Export Market Intelligence: India's 54 Suppliers Shipping to 46 Countries — TransData Nexus 2026

Q: Who are the top ertapenem exporters from India?

The top ertapenem exporters from India are: 1. EUGIA PHARMA SPECIALITIES LIMITED — $76.7M (70.4% market share); 2. JODAS EXPOIM PRIVATE LIMITED — $7.4M (6.8% market share); 3. GLAND PHARMA LIMITED — $7.0M (6.4% market share); 4. DR.REDDY'S LABORATORIES LTD — $6.1M (5.6% market share); 5. GLAND PHARMA LTD — $2.4M (2.2% market share). Together they account for 91.4% of India's total ertapenem export value.

Q: What is the total export value of ertapenem from India?

The total export value of ertapenem from India is $109.0M USD, recorded across 780 shipment transactions from 54 active exporters to 46 destination countries. The average shipment value is $139.8K.

Q: Which countries import ertapenem from India?

India exports ertapenem to 46 countries worldwide. The top importing countries are: UNITED STATES (54.9% share, $59.9M), MALTA (15.7% share, $17.1M), RUSSIA (6.8% share, $7.4M), CANADA (6.3% share, $6.8M), BRAZIL (4.5% share, $4.9M). These five markets account for 88.1% of total export value.

Q: What is the HS code for ertapenem exports from India?

The primary HS code for ertapenem exports from India is 30042099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of ertapenem exports from India?

The average unit price for ertapenem exports from India is $20.70 USD per unit, with prices ranging from $0.05 to $2205.87 depending on formulation, packaging, and order volume. The total market is valued at $109.0M across 780 shipments.

Q: Which ports handle ertapenem exports from India?

The primary ports for ertapenem exports from India are DELHI AIR CARGO ACC (INDEL4) (31.8% of shipments), DELHI AIR (23.7% of shipments), Delhi Air (9.1% of shipments), HYDERABAD ACC (INHYD4) (6.7% of shipments), HYDERABAD AIR (4.2% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of ertapenem?

India is one of the world's leading exporters of ertapenem due to its large base of 54 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports ertapenem to 46 countries, demonstrating 24% global market coverage.

Q: What certifications do Indian ertapenem exporters need?

Indian ertapenem exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import ertapenem from India?

There are 137 registered buyers importing ertapenem from India, spread across 46 countries. The repeat buyer rate is 58.4%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top ertapenem supplier from India?

EUGIA PHARMA SPECIALITIES LIMITED is the leading ertapenem exporter from India with a market share of 70.4% and total export value of $76.7M across 537 shipments. The top 5 suppliers together control 91.4% of total export value.

Suresh Sormare

Ertapenem

India Pharmaceutical Trade Intelligence

$109.0M54 Suppliers46 CountriesHS 30042099

ExportsIndia → UNITED STATES54.9%India → MALTA15.7%

ImportsUNITED STATES → India$34.5K AUSTRALIA → India$9.3K

#1 Supplier: EUGIA PHARMA #1 Buyer: EUGIA US

Ertapenem Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Ertapenem to the World

Between 2022 and 2026, India exported $109.0M worth of ertapenem across 780 verified shipments to 46 countries — covering 24% of world markets in the Advanced Antibiotics segment. The largest destination is UNITED STATES (54.9%). EUGIA PHARMA SPECIALITIES LIMITED leads with a 70.4% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Ertapenem export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Ertapenem export data snapshot — $109.0M · 54 exporters · 46 countriesTransData Nexus · Indian Customs Data

Top Ertapenem Exporters from India

54 active exporters · Ranked by export value

View all 54 →

Top Ertapenem Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	EUGIA PHARMA SPECIALITIES LIMITED	$76.7M	537	11	70.4%
2	JODAS EXPOIM PRIVATE LIMITED

Top Countries Importing Ertapenem from India

46 destination markets · Ranked by import value

All 46 countries →

Top Countries Importing Ertapenem from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	UNITED STATES	$59.9M	54.9%
2	MALTA	$17.1M	15.7%
3	RUSSIA	$7.4M	6.8%
4	CANADA	$6.8M	6.3%
5	BRAZIL	$4.9M	4.5%
6	UNITED KINGDOM	$2.1M	1.9%
7	BELGIUM	$1.9M	1.7%
8	SOUTH AFRICA	$1.8M	1.7%
9	COSTA RICA	$1.2M	1.1%
10	PERU	$828.5K	0.8%

UNITED STATES is India's largest ertapenem export destination, absorbing 54.9% of total exports worth $59.9M. The top 5 importing countries — UNITED STATES, MALTA, RUSSIA, CANADA, BRAZIL — together account for 88.1% of India's total ertapenem export value. The remaining 41 destination countries collectively receive the other 11.9%, indicating a focused distribution strategy targeting key markets.

Who Supplies Ertapenem to India?

3 origin countries · Total import value: $43.8K

India imports ertapenem from 3 countries with a combined import value of $43.8K. The largest supplier is UNITED STATES ($34.5K, 8 shipments), followed by AUSTRALIA and CHINA. All values are from Indian Customs (DGFT) import records.

Countries Supplying Ertapenem to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	UNITED STATES	$34.5K	8	78.7%
2	AUSTRALIA	$9.3K	3	21.3%
3	CHINA	$10	1	0.0%

UNITED STATES is the largest supplier of ertapenem to India, accounting for 78.7% of total import value. Click any country to see detailed supplier and buyer data for that import corridor.

Regulatory Landscape — Ertapenem

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, Ertapenem is approved for various indications, including the treatment of complicated intra-abdominal infections, complicated skin and skin structure infections, and community-acquired pneumonia. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for Ertapenem, indicating a competitive generic market. Recent approvals include those granted in March 2025 and July 2025. As of March 2026, there are no active FDA import alerts specifically targeting Ertapenem, suggesting compliance with regulatory standards. The substantial export volume to the U.S., accounting for 54.9% of India's total Ertapenem exports, underscores the significance of the U.S. market for Indian manufacturers.

2EU & UK Regulatory Framework

In the European Union, the European Medicines Agency (EMA) oversees the approval and regulation of medicines, including Ertapenem. Ertapenem has received marketing authorization in several EU member states, adhering to the EU's Good Manufacturing Practice (GMP) requirements. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) continues to regulate Ertapenem post-Brexit, ensuring compliance with UK-specific GMP standards. The significant export to Malta (15.7%) reflects the strategic role of certain EU countries in the distribution of pharmaceuticals within the region.

3WHO Essential Medicines & Global Standards

Ertapenem is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025, highlighting its importance in treating priority health conditions. The WHO's inclusion emphasizes the need for its availability and affordability globally. Ertapenem formulations are standardized across major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring consistent quality and efficacy.

4India Regulatory Classification

In India, Ertapenem is classified under Schedule H1 of the Drugs and Cosmetics Rules, indicating that it is a prescription drug subject to specific regulatory controls to prevent misuse. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on Ertapenem as of March 2026, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) for certain pharmaceuticals; however, Ertapenem is not currently listed among those requiring an export NOC, facilitating smoother international trade.

5Patent & Exclusivity Status

The primary patents for Ertapenem have expired, leading to increased generic competition globally. This patent expiration has enabled multiple manufacturers to enter the market, contributing to the competitive pricing observed in export data.

6Recent Industry Developments

In June 2025, the Indian Ministry of Health and Family Welfare revised the National List of Essential Medicines, reaffirming Ertapenem's inclusion, which underscores its critical role in the healthcare system. In October 2025, the NPPA conducted a review of antibiotic pricing, including Ertapenem, but opted not to impose a ceiling price, maintaining market-driven pricing mechanisms. In December 2025, the CDSCO issued updated guidelines for the manufacturing of carbapenem antibiotics, emphasizing stringent quality control measures to ensure product efficacy and safety. In February 2026, the WHO released a report on antimicrobial resistance, highlighting the importance of antibiotics like Ertapenem in combating resistant infections and urging prudent use to preserve their effectiveness. In March 2026, the EMA approved a new generic version of Ertapenem, further increasing competition and potentially reducing prices within the European market.

These developments reflect the dynamic regulatory and market landscape for Ertapenem, emphasizing the need for continuous monitoring to navigate the complexities of international pharmaceutical trade effectively.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Ertapenem

Retail & reference prices across 9 markets vs. India FOB export price of $20.70/unit

Global Price Benchmark for Ertapenem across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$150	USD	Pricing data sourced from the FDA's Orange Book and Medicare Part B Drug Average Sales Price (ASP) files as of March 2026.
United Kingdom	$130	GBP	According to the NHS Drug Tariff, as of March 2026.
Germany	$135	EUR	Based on the Lauer-Taxe, the official German pharmaceutical pricing reference, as of March 2026.
Australia	$140	AUD

Supply Chain Risk Assessment — Ertapenem

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

Ertapenem, a broad-spectrum carbapenem antibiotic, is primarily manufactured in India. However, the production of its Active Pharmaceutical Ingredient (API) heavily relies on Key Starting Materials (KSMs) sourced from China. This dependency is part of a broader trend where 41% of KSMs used in U.S.-approved APIs are solely sourced from China, and 16% from India, as reported by the U.S. Pharmacopeia in October 2025.

The reliance on Chinese KSMs introduces significant vulnerabilities. For instance, in September 2025, China reduced the prices of 41 APIs and KSMs by 40% to 50%, aiming to undercut Indian manufacturers. This aggressive pricing strategy has adversely affected the competitiveness of Indian API producers, including those manufacturing Ertapenem.

2Supplier Concentration & Single-Source Risk

Our proprietary trade data from 2022 to 2026 indicates a high supplier concentration in Ertapenem exports from India. The top five exporters account for 91.4% of the total export value, with EUGIA PHARMA SPECIALITIES LIMITED alone contributing 70.4%. Such concentration poses a significant single-source risk; any disruption in these key suppliers could severely impact global Ertapenem availability.

To mitigate this risk, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic API production and reduce reliance on imports. In November 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, essential for antibiotics production. While this initiative aims to enhance self-sufficiency, its impact on diversifying Ertapenem suppliers remains to be seen.

Access Complete Ertapenem Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 780 transactions across 46 markets.

Request Demo View Pricing

Frequently Asked Questions — Ertapenem Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top ertapenem exporters from India?

The leading ertapenem exporters from India are EUGIA PHARMA SPECIALITIES LIMITED, JODAS EXPOIM PRIVATE LIMITED, GLAND PHARMA LIMITED, and 9 others. EUGIA PHARMA SPECIALITIES LIMITED leads with 70.4% market share ($76.7M). The top 5 suppliers together control 91.4% of total export value.

What is the total export value of ertapenem from India?

The total export value of ertapenem from India is $109.0M, recorded across 780 shipments from 54 active exporters to 46 countries. The average shipment value is $139.8K.

Which countries import ertapenem from India?

India exports ertapenem to 46 countries. The top importing countries are UNITED STATES (54.9%), MALTA (15.7%), RUSSIA (6.8%), CANADA (6.3%), BRAZIL (4.5%), which together account for 88.1% of total export value.

What is the HS code for ertapenem exports from India?

The primary HS code for ertapenem exports from India is 30042099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Ertapenem

Ertapenem

Top Ertapenem Exporters from India

Top Countries Importing Ertapenem from India

Who Supplies Ertapenem to India?

Quick Facts

Related Advanced Antibiotics

Related Analysis

Need Details?

Regulatory Landscape — Ertapenem

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Ertapenem

Supply Chain Risk Assessment — Ertapenem

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Ertapenem Trade Intelligence

Frequently Asked Questions — Ertapenem Exports from India

Who are the top ertapenem exporters from India?

What is the total export value of ertapenem from India?

Which countries import ertapenem from India?

What is the HS code for ertapenem exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of ertapenem exports from India?

Which ports handle ertapenem exports from India?

Why is India a leading exporter of ertapenem?

What certifications do Indian ertapenem exporters need?

How many buyers import ertapenem from India?

What is the market share of the top ertapenem exporter from India?

Analysis Methodology